Monday, 22 January 2018

Comorbidties and smoking, what can we do about them?

The elephant in the room is comorbidities such as hypertension, diabetes, obesity, metabolic syndrome and smoking. How can we get pwMS to take their general health seriously? 

Sunday, 21 January 2018

Has NICE got it wrong this time?

As you are probably aware NICE, true to past form, chose the Christmas period to toss a small grenade into the MS space. I assume they thought that by tossing it on Wednesday 20 December when most people were either away, or about to go away, on Christmas holidays the perceived explosion would be smaller than expected and the shrapnel would cause no collateral damage. NICE was wrong. They are wrong for several reasons.

Saturday, 20 January 2018

What is causing the MS pandemic?

Is it not the time to do something about the obesity pandemic? What has obesity got to do with MS? 

Friday, 19 January 2018

Imaging grey matter atrophy to find the roots of disability

How do we measure nerve loss?

The imagers tell us it is grey matter loss that holds the key.

So what's new here?

Wednesday, 17 January 2018

Is HSCT for everyone, or not?

The HSCT zealots would want you to believe that HSCT is the solution to MS and that we the neurologists are preventing you from accessing this curative treatment. Are they correct? Or do we need evidence from randomised trials?

Monday, 15 January 2018

Imaging Demyelination, but am I being a bit thick?

A new report suggests that there is a new imaging agent for demyelination.

If we can image demyelination, remyelination trials get a whole lot easier.

However you asked, Has this study in animals cracked the nut?

Future Directions for Laboratory Animal Law in the US

Animals in Research is an Integral part of MS research.

Like or Loathe it, it is occurring, but times are changing.

Do you want to listen to a Day Webinar?

Future Directions for Laboratory Animal Law in the United States

Sunday, 14 January 2018

Making T reg cells. Explaining the daclizumab conundrum

How does daclicumab work?

Are immunologists fudging the mechanisms to keep dogma alive?

Friday, 12 January 2018

Newsflash: the wait is over ocrelizumab finally gets its EU marketing authorisation

If you have PPMS, and live in Europe, you are one step closer to having a disease-modifying therapy for your MS.

Guest post: FAIR data for next generation management of MS

Transforming the population based management of today into an individualized, personalized and precision level management is a major goal in research. I believe, the key to reach this next level is FAIR data.

Thursday, 11 January 2018

Guest post: Familial MS: do your genes seal your fate?

MS is not considered a hereditary disorder, as there is no specific gene transmitted from parent to child that causes the disease (not yet confirmed! We've covered the topic on the blog before). However, around 20% of people with MS report another family member with the condition and the risk differs depending on the degree of relatedness.

Wednesday, 10 January 2018

Monday, 8 January 2018

HSCT on the Increase

How common is HSCT being performed as a treatment for MS and which countries are using it most? 

You may be surprised by the results. 

Sunday, 7 January 2018

Regional Specific Astrocyte Function for Repair and how cholesterol may link to Repair

EAE gets explained in many ways and you asked about a report on how researchers find a way to repair nerves. 
Is this the right view, because we are about to do a trial that will do the exact opposite?

Well not Quite the opposite. Is the cholesterol pathway opening the door to repair

Saturday, 6 January 2018

Walking the talk, but too slowly: one #MSBrainAttack too many

How quickly should we treat MS? As soon as possible. 

I made the case on behalf of DrK last month for a natalizumab Brain Attack Trial? I now have a personal clinical anecdote why we should not delay things any longer.

Friday, 5 January 2018

Taxis for wheelchair users!

In a time where research is making so many developments, we aren't getting the basics of patient experience right.

Taxi, taxi, taxi, .....

Thursday, 4 January 2018

2017: Reflections on another year in multiple sclerosis

Depending on how you see the world, i.e. through rose-tinted glasses, you may reflect on 2017 as being a landmark year for the field of MS.

Prof G's rose-tinted view of the world!

The following are 10 of my highlights, and a few lowlights, from 2017.

Wednesday, 3 January 2018

Why is MS more common in women?

Last month, I attended ‘MS At the Limits’, and the final talk by Dr Riley Bove (University of California, San Francisco) was truly fascinating. I know I am a bit delayed in posting this but I thought I would share some of the key points…

Tuesday, 2 January 2018

Trust me it's good for you!

On how patients with multiple sclerosis weigh side effect severity and treatment efficacy when making treatment decisions.

Monday, 1 January 2018

Happy New Year Q&A Jan 2018

Happy New Year!

For those who want to say something unrelated to the posts this the place for you.

So whilst ProfG prepares a year that was, it is a two-way street